| Nivolumab versus everolimus in advanced renal-cell carcinoma RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ... New England Journal of Medicine 373 (19), 1803-1813, 2015 | 6052 | 2015 |
| Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer H Joensuu, PL Kellokumpu-Lehtinen, P Bono, T Alanko, V Kataja, ... New England Journal of Medicine 354 (8), 809-820, 2006 | 1912 | 2006 |
| Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, ... Annals of oncology 25 (8), 1544-1550, 2014 | 1359 | 2014 |
| Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial SJ Antonia, JA López-Martin, J Bendell, PA Ott, M Taylor, JP Eder, ... The Lancet Oncology 17 (7), 883-895, 2016 | 1328 | 2016 |
| One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial H Joensuu, M Eriksson, KS Hall, JT Hartmann, D Pink, J Schütte, ... Jama 307 (12), 1265-1272, 2012 | 1168 | 2012 |
| Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial P Sharma, MK Callahan, P Bono, J Kim, P Spiliopoulou, E Calvo, ... The lancet oncology 17 (11), 1590-1598, 2016 | 736 | 2016 |
| Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the … H Joensuu, P Bono, V Kataja, T Alanko, R Kokko, R Asola, T Utriainen, ... Journal of Clinical Oncology 27 (34), 5685-5692, 2009 | 580 | 2009 |
| VEGF and angiopoietin signaling in tumor angiogenesis and metastasis P Saharinen, L Eklund, K Pulkki, P Bono, K Alitalo Trends in molecular medicine 17 (7), 347-362, 2011 | 542 | 2011 |
| Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study B Escudier, C Porta, P Bono, T Powles, T Eisen, CN Sternberg, ... Journal of Clinical Oncology 32 (14), 1412-1418, 2014 | 480 | 2014 |
| Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule DJ Smith, M Salmi, P Bono, J Hellman, T Leu, S Jalkanen The Journal of experimental medicine 188 (1), 17-27, 1998 | 382 | 1998 |
| Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor) MC Heinrich, GA McArthur, GD Demetri, H Joensuu, P Bono, R Herrmann, ... Journal of Clinical Oncology 24 (7), 1195-1203, 2006 | 372 | 2006 |
| Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1 … PA Ascierto, I Melero, S Bhatia, P Bono, RE Sanborn, EJ Lipson, ... Journal of Clinical Oncology 35 (15_suppl), 9520-9520, 2017 | 271 | 2017 |
| Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma M Heinonen, P Bono, K Narko, SH Chang, J Lundin, H Joensuu, ... Cancer research 65 (6), 2157-2161, 2005 | 259 | 2005 |
| High LYVE-1–positive lymphatic vessel numbers are associated with poor outcome in breast cancer P Bono, VM Wasenius, P Heikkilä, J Lundin, DG Jackson, H Joensuu Clinical Cancer Research 10 (21), 7144-7149, 2004 | 249 | 2004 |
| Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial H Joensuu, M Eriksson, K Sundby Hall, A Reichardt, JT Hartmann, D Pink, ... Journal of Clinical Oncology 34 (3), 244-250, 2016 | 235 | 2016 |
| Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results P Sharma, A Siefker-Radtke, F de Braud, U Basso, E Calvo, P Bono, ... Journal of Clinical Oncology 37 (19), 1608-1616, 2019 | 216 | 2019 |
| Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase … K Fizazi, C Massard, P Bono, R Jones, V Kataja, N James, JA Garcia, ... The lancet oncology 15 (9), 975-985, 2014 | 212 | 2014 |
| CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73. L Airas, J Hellman, M Salmi, P Bono, T Puurunen, DJ Smith, S Jalkanen The Journal of experimental medicine 182 (5), 1603-1608, 1995 | 184 | 1995 |
| Layilin, a novel integral membrane protein, is a hyaluronan receptor P Bono, K Rubin, JMG Higgins, RO Hynes Molecular biology of the cell 12 (4), 891-900, 2001 | 180 | 2001 |
| Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). H Joensuu, M Eriksson, J Hatrmann, K Sundby Hall, J Schutte, ... Journal of Clinical Oncology 29 (18_suppl), LBA1-LBA1, 2011 | 179 | 2011 |
